Article
ESMO: AstraZeneca's targeted lung cancer med Tagrisso slashes CNS recurrence by 82%
Rating:
0.0
Views:
108
Likes:
1
Library:
1
Once EGFR-mutated lung cancer spreads to the brain, a patient's prognosis dramatically worsens. And that's what AstraZeneca's Tagrisso is trying to prevent in postsurgery patients. Turns out, the drug can do it pretty well, according to a CNS analysis of the phase 3 Adaura trial
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value